Somewhat Positive News Coverage Somewhat Unlikely to Affect Microbot Medical (MBOT) Share Price

News stories about Microbot Medical (NASDAQ:MBOT) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Microbot Medical earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.3936317128209 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the headlines that may have impacted Accern’s scoring:

Shares of Microbot Medical (NASDAQ MBOT) remained flat at $$1.04 during midday trading on Monday. 379,500 shares of the stock traded hands, compared to its average volume of 883,814. Microbot Medical has a twelve month low of $1.00 and a twelve month high of $9.94.

In other news, Director Yoseph Bornstein sold 32,067 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $1.03, for a total value of $33,029.01. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Moshe Shoham sold 33,700 shares of the firm’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $1.50, for a total transaction of $50,550.00. The disclosure for this sale can be found here. Insiders sold a total of 490,301 shares of company stock worth $590,628 in the last ninety days. Insiders own 31.83% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Microbot Medical (MBOT) Share Price” was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2017/12/25/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-microbot-medical-mbot-share-price-2.html.

About Microbot Medical

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Insider Buying and Selling by Quarter for Microbot Medical (NASDAQ:MBOT)

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply